PE Tech Report


Like this article?

Sign up to our free newsletter

Neuraxpharm acquires Brain Therapeutics

Neuraxpharm Group (Neuraxpharm), a European specialty pharmaceutical company focused on the central nervous system (CNS), has expanded its business in Southeast Europe through the acquisition of Brain Therapeutics, a CNS-focused marketing and distribution company with expertise in the commercialisation of CNS products in Greece, Cyprus and the Balkan countries.


Having acquired Brain Therapeutics, Neuraxpharm is now able to bring new products to the Greek market since the platform offers a unique level of local market access. The commercial expertise of Brain Therapeutics and the availability of necessary licenses for the broad product portfolio will enable Neuraxpharm to expand its offering rapidly and build on its position as a CNS specialist in Southeast Europe. The market-leading product for emergency treatment of children and adolescents with epilepsy, Buccolam®, will be among the products to be offered. 

The terms of the transaction have not been disclosed.

Like this article? Sign up to our free newsletter